Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery

Semarion develops cell assay technology that enables adherent cell models to be handled as assay-ready, barcoded reagents. Its platform is used by pharmaceutical and life sciences organisations to improve flexibility, scalability and data generation in drug discovery workflows.